Rajan Gadhia1, David McCane2, Jason Lee2, Ken Chyuan Ling2, Kevin Jiang3, David Chiu2. 1. Houston Methodist Hospital Neurological Institute, Houston, Texas. Electronic address: rrgadhia@houstonmethodist.org. 2. Houston Methodist Hospital Neurological Institute, Houston, Texas. 3. Rice University, Houston, Texas.
Abstract
BACKGROUND: We present a single institution registry with the novel feature of 90-day outcome assessments on all hospitalized acute stroke patients, inclusive of every patient with a primary discharge diagnosis of transient ischemic attack (TIA), acute ischemic stroke (AIS), nontraumatic subarachnoid hemorrhage (SAH), and intracerebral hemorrhage (ICH). METHODS: Patient data obtained in the HOPES registry include demographics, comorbid diagnoses, medications, health behaviors, laboratory values, imaging studies, vital signs, and outcome measures, most notably the modified Rankin Scale (mRS) at 90days. RESULTS: From May 2016 to December 31, 2017, 1607 patients were enrolled in the HOPES registry. 90-day outcome assessments were captured on 1555 patients (97%): 1096 AIS, 230 ICH, 110 SAH, and 119 TIA patients. Mortality rates and 90-day outcomes were most favorable for TIA patients. Mortality and 90-day disability scores were poorest for patients in the ICH group. CONCLUSIONS: The inclusion of 90-day outcomes data will allow HOPES to stand apart among stroke registries as a new standard for stroke outcomes research. The registry will provide the necessary comprehensive data that the field needs as we transition our focus of stroke research to poststroke recovery.
BACKGROUND: We present a single institution registry with the novel feature of 90-day outcome assessments on all hospitalized acute strokepatients, inclusive of every patient with a primary discharge diagnosis of transient ischemic attack (TIA), acute ischemic stroke (AIS), nontraumatic subarachnoid hemorrhage (SAH), and intracerebral hemorrhage (ICH). METHODS:Patient data obtained in the HOPES registry include demographics, comorbid diagnoses, medications, health behaviors, laboratory values, imaging studies, vital signs, and outcome measures, most notably the modified Rankin Scale (mRS) at 90days. RESULTS: From May 2016 to December 31, 2017, 1607 patients were enrolled in the HOPES registry. 90-day outcome assessments were captured on 1555 patients (97%): 1096 AIS, 230 ICH, 110 SAH, and 119 TIApatients. Mortality rates and 90-day outcomes were most favorable for TIApatients. Mortality and 90-day disability scores were poorest for patients in the ICH group. CONCLUSIONS: The inclusion of 90-day outcomes data will allow HOPES to stand apart among stroke registries as a new standard for stroke outcomes research. The registry will provide the necessary comprehensive data that the field needs as we transition our focus of stroke research to poststroke recovery.
Authors: Destiny Hooper; Tariq Nisar; David McCane; Jason Lee; Ken Chyuan Ling; Farhaan Vahidy; Kelvin Wong; Stephen Wong; David Chiu; Rajan Gadhia Journal: Cureus Date: 2021-02-04
Authors: Shruti Agashe; Destiny Hooper; Tariq Nisar; David McCane; Jason Lee; Ken Chyuan Ling; Farhaan S Vahidy; David Chiu; Rajan R Gadhia Journal: Epilepsy Behav Rep Date: 2021-01-07
Authors: Tanu Garg; Shyam Panchal; Tariq Nisar; David McCane; Jason Lee; Ken Chyuan Ling; Barry Trachtenberg; Arvind Bhimaraj; David Chiu; Rajan Gadhia Journal: Cureus Date: 2021-05-25